Data Concepts and Terminology Standards for Clinical Research and Drug Development (U24)
The summary for the Data Concepts and Terminology Standards for Clinical Research and Drug Development (U24) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Food Drug Administration, which is the U.S. government agency offering this grant.
Data Concepts and Terminology Standards for Clinical Research and Drug Development (U24): The Center for Drug Evaluation and Research (CDER) receives a vast and growing amount of data in a variety of regulatory submissions from a multitude of sources and in a variety of formats. This wealth of data holds great potential to advance CDERs regulatory and scientific work, but the present lack of standardized data creates significant challenges to realizing that potential. The volume and complexity of drug-related information submitted to CDER for regulatory review is creating significant challenges to the Centers ability to efficiently and effectively perform its critical public health mission. The lack of standardized data affects CDERs review processes by curtailing a reviewers ability to perform integral tasks such as rapid acquisition, analysis, storage and reporting of regulatory data. Improved data quality, accessibility and predictability will give reviewers more time to carry out complex analyses, ask in-depth questions and address late-emerging issues. Standardized data will allow reviewers to increase review consistency and perform evaluations across the drug lifecycle. This will enhance the Centers performance across key drug regulatory functions and ongoing business operations, including pre-market review, post-market safety, oversight of drug quality, and oversight of drug promotion. In accordance with the Office of Management and Budget (OMB) Circular A-119, the FDA will: use voluntary, consensus-based standards development processes in place of government unique standards unless such standards are inconsistent with law or otherwise impractical; advocate to align these standards with existing health information technology initiatives, laws, regulations, and mandates; and promote coordination with other standards currently in use. The projects selected under this funding opportunity must adhere to these principles. OVERARCHING PROGRAM GOAL: The CDER Data Standards Program's goals are: Support open, consensus-based data standards development Maintain and promote a well-defined data standards governance function Promote the electronic submission of regulatory data using established standards Optimize the regulatory review process to fully leverage data conformed to standards PROGRAM PRIORITIES: The Food and Drug Administration is announcing the availability of cooperative agreements for the development of data concepts and terminology standards to support human drug development and evaluation. The primary objective is to support the development of non-proprietary, consensus-based data standards for use in clinical studies of human drugs and biologics. Projects may focus on the identification of solutions to data standards development and their challenges in areas, such as general clinical and nonclinical study data, specific therapeutic areas, as well as other sections of the regulatory submission (e.g., quality / Chemistry, Manufacturing, and Controls (CMC)). DESCRIPTION: The application must include: An overall program plan describing the approach, process to be used in developing the selected area for standardization, any specific technologies to be utilized and experience with those technologies, and deliverables A method (e.g., Gantt chart) to plan and track progress toward specific deliverables under this award for the purpose of reporting the status to the FDA and its stakeholders. At a minimum, information reported should include a listing of interim steps necessary to complete a given deliverable, the timeline for completing those tasks, and a report of any issues in meeting those established deadlines. Definition of scope to be addressed (e.g., use case) during the project period Description of the result (concept, terminology, domain, therapeutic area) to be developed in the application (e.g., completed implementation guide) Description of the coordination/collaboration (to achieve consensus) needed to address the area of standardization including by not limited to: engagement of subject matter experts, organizations, standards development organizations, affected stakeholders How the standard being addressed aligns with currently available standards and approach to making the standard publically available A description of the experience of the principal investigators (PI), who is/are the Program Director (PD), should be described, together with his/her/their involvement in the projects. It is expected that PI(s) should have experience with data standards development as the PI(s) have the ultimate responsibility for the successful outcomes of the projects Specific Areas of Research Interest: FDA/CDER is specifically interested in projects to develop standardized clinical research concepts and terminology for therapeutic areas with significant drug development pipeline activity, emerging or complex analytical challenges, and/or are of significant public health concern. The list of therapeutic areas with current status is available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/ucm287408.htm.
|Federal Grant Title:||Data Concepts and Terminology Standards for Clinical Research and Drug Development (U24)|
|Federal Agency Name:||Food Drug Administration|
|Grant Categories:||Health Information and Statistics Science and Technology|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-FD-14-004|
|Type of Funding:||Cooperative Agreement|
|CFDA Descriptions:||Food and Drug Administration_Research|
|Current Application Deadline:||Jun 16, 2014|
|Original Application Deadline:||Jun 16, 2014|
|Posted Date:||Apr 29, 2014|
|Creation Date:||Apr 29, 2014|
|Archive Date:||Jul 16, 2014|
|Total Program Funding:||$1,000,000|
|Maximum Federal Grant Award:||$225,000|
|Minimum Federal Grant Award:||$200,000|
|Expected Number of Awards:||4|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
City or township governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
Public housing authorities/Indian housing authorities
Private institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
For profit organizations other than small businesses
Independent school districts
Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Additional Information on Eligibility
- Foreign Organizations
- Link to Full Grant Announcement
- Copy of published RFA
- Grant Announcement Contact
- Gladys Melendez-Bohler
Grants Management Officer/Specialist
Food & Drug Administration 301-443-5869
- Similar Government Grants
- • FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)
- • Drug Development Tools Research Grants (U01 Clinical Trial Not Allowed)
- • Rare Disease Clinical Outcome Assessment Consortium (U01 Clinical Trial Not Allowed)
- • Cigar Tobacco Reference Products Program (UC2) Clinical Trials Not Allowed
- • Implementation of U.S. Food Safety Modernization Act - Identifying, Researching, and Imple...
- • Support for Small Scientific Conference Grant Program
- • Cooperative Agreement to Support the World Health Organization (WHO) International Program...
- • Clinical Studies of Safety and Effectiveness of Orphan Products
- More Grants from the Food Drug Administration
- • NARMS Cooperative Agreement Program to Enhance and Strengthen Antibiotic Resistance Survei...
- • Cooperative Agreement to Support Shellfish Safety Assistance Project (U01)
- • Native American Tribes Outreach, Education, and Training to Enhance Food Safety and FSMA C...
- • Local Food Producer Outreach, Education, and Training to Enhance Food Safety and FDA Food ...
- • National Training, Education, Extension, Outreach, and Technical Assistance Competitive Gr...